Use of Johnson & Johnson's Covid-19 vaccine should be resumed in the United States, advisers to US health regulators have said, after weighing evidence of the shot's link to extremely rare but potentially deadly blood clots.
The recommendation paves the way for J&J's shot to begin going into arms again in the United States, once they are confirmed by regulators.
The US Centers for Disease Control and Prevention and the US Food and Drug Administration paused its use last week in order to review reports of the blood clot condition accompanied by low blood platelets.
The FDA will update the emergency use authorisation for the vaccine to include information about the risk and how to recognise and treat the condition, J&J executives told the